GH News

(NASDAQ:GH) PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the appointment of Alex M. Azar II to its board of directors, effective immediately. As the 24th Secretary of the U.S. Department of Health and Human Services (HHS), Secretary Azar had oversight and management of agencies critical to all Americans’ health care including the Centers for Medicare and Medicaid Services, the Food and Drug Administration, and the Center for D

(NASDAQ:GH) PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it has reached a strategic agreement with LabFlorida/SunDx Labs to provide residents of senior living communities access to Guardant Shield™, the first blood test approved by the U.S. Food and Drug Administration (FDA) as a primary screening option for colorectal cancer (CRC). As part of the agreement, LabFlorida will serve as the exclusive distributor to senior living c

(NASDAQ:GH) PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a strategic partnership with PathGroup, one of the nation’s leading partners to physicians, hospitals, and healthcare networks nationwide, to significantly expand the reach of Guardant’s FDA-approved Shield™ blood test. The partnership will bring Shield to more than 250 hospitals and health systems, over 15,000 PathGroup-affiliated physicians across 25 states, and allow

(NASDAQ:GH) PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a positive clinical readout update assessing the performance of the latest colorectal cancer (CRC) screening algorithm (V2) for its Shield™ blood test. The study met all primary endpoints and the sensitivity of this new screening algorithm for detecting CRC was 84% with 90% specificity. Sensitivity for detection of stage I CRC was 62%. “We are pleased with the performanc

(NASDAQ:GH) PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be hosting an Investor Day on September 24, 2025, in New York City, NY starting at 9:00 a.m. Eastern Time / 6:00 a.m. Pacific Time. The event will feature presentations by several members of the company's leadership team. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: ww

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the upcoming Morgan Stanley 23rd Annual Global Healthcare Conference in New York, NY. Guardant Health’s management is scheduled to participate in a fireside chat on Monday, September 8th at 4:05 p.m. ET. Interested parties may access live and archived webcasts of the sessions on the “Investors” section of the company website at: www.guarda

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on July 22, 2025, the Compensation Committee of Guardant’s Board of Directors approved the granting of restricted stock units (“RSUs”) representing 239,565 shares of its common stock to 189 new non-executive employees and two non-qualified stock option awards to purchase 23,542 shares of its common stock to two new non-executive employees with a grant date of August

SAN FRANCISCO--(BUSINESS WIRE)---- $GH--The American Cancer Society (ACS) today announced a new partnership with Guardant Health (Nasdaq: GH), a leading precision oncology company focused on improving access to cancer screening and advancing health equity. This collaboration supports ACS’s nationwide cancer screening efforts, including the I Love You, Get Screened public awareness campaign; community-based health system partnerships; and state coalition work aimed at removing barriers to lifesaving scr

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield blood test for colorectal cancer (CRC) screening has been named a winner of Fast Company’s 2025 World Changing Ideas Awards. These annual awards recognize innovative companies and projects addressing the world’s most urgent challenges. Shield is the first blood test approved by the U.S. Food and Drug Administration (FDA) as a primary screening option for CRC.

Guardant Health's Shield test receives FDA breakthrough status and NCCN guideline inclusion, with high accuracy shown in new ASCO and ECLIPSE study data.

Guardant Health partners with Pfizer to support oncology drug development using smart liquid biopsy tech and expand testing access in China.

CMS approves ADLT status for Guardant Health's Shield test, setting Medicare reimbursement at $1,495. The analyst sees a potential revenue boost from the decision.